drugset / Trial / NCT04076371

The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia

NCT04076371

Completed 1640 enrolled Beijing HuiLongGuan Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

A randomized, double-blind trial of the treatment effect of dose-low antipsychotics combined with low-dose sertraline in 1640 schizophrenia patients

Timeline

Start
2012-01
Primary completion
2018-12
Completion
2018-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 7.5 mg
Subject Olanzapine Small molecule 10 mg
Subject Olanzapine Small molecule 12.5 mg
Subject Olanzapine Small molecule 20 mg
Subject Paliperidone Unknown 3 mg
Subject Paliperidone Unknown 4.5 mg
Subject Paliperidone Unknown 6 mg
Subject Paliperidone Unknown 9 mg
Subject Risperidone Other / unclassified 2 mg
Subject Risperidone Other / unclassified 3.5 mg
Subject Risperidone Other / unclassified 4 mg
Subject Risperidone Other / unclassified 6 mg
Subject Sertraline Small molecule 50 mg
Subject Sertraline Small molecule 100 mg
Subject Ziprasidone Small molecule 60 mg
Subject Ziprasidone Small molecule 100 mg
Subject Ziprasidone Small molecule 120 mg
Subject Ziprasidone Small molecule 160 mg

Indications